Biocept inc (BIOC)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Cash Flows from Operating Activities
Net loss

-25,138

-24,571

-21,613

-18,399

-16,949

-15,866

-9,233

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

931

800

575

322

261

251

266

Amortization of right-of-use assets

-158

-

-

-

-

-

-

Inventory reserve

-14

38

50

31

34

13

-

Inventory reserve

-

-

-

-

-

-

70

Stock-based compensation

869

623

1,247

1,593

1,377

1,822

952

Non-cash interest expense related to credit facility and other financing activities

-

29

45

100

119

1,445

2,066

Warrant inducement expense

1,831

-

-

-

-

-

-

Gain on sale of fixed assets

-

-

-

30

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

200

-782

Increase/(decrease) in cash resulting from changes in:
Accounts receivable, net

1,952

380

1,064

94

23

1

-9

Inventory

194

50

-100

168

126

82

-38

Prepaid expenses and other current assets

-523

-488

-518

-494

80

401

37

Other non-current assets

-

-

-

-

-

-0

-268

Accounts payable

14

601

349

332

-51

-981

-175

Accrued liabilities

210

460

236

165

240

-1,046

233

Accrued interest

-

-202

78

55

110

58

-

Deferred rent

-

-116

-76

-36

1

38

259

Net cash used in operating activities

-23,049

-22,355

-19,650

-

-

-

-

Cash Flows from Investing Activities:
Net cash used in operating activities

-

-

-

-15,697

-15,154

-14,575

-6,202

Proceeds from sale of fixed assets

-

-

-

30

-

-

-

Purchases of fixed assets

735

145

1,400

482

165

394

0

Net cash used in investing activities

-735

-145

-1,400

-

-

-

-

Cash Flows from Financing Activities:
Net cash used in investing activities

-

-

-

-451

-165

-394

-0

Net proceeds from issuance of common stock and warrants

25,744

25,693

13,505

13,771

9,788

-

-

Proceeds from exercise of common stock warrants

2,513

1

7,498

-

9,760

-

-

Payments on finance leases

539

160

-

-

-

-

-

Proceeds from exercise of overallotment warrants

2,337

-

-

-

-

-

-

Net proceeds from sale-leaseback transaction

-

-

150

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

20

Payments for repurchase of shares

-

-

-

-

-

-

4

Payments on equipment financings

-

-

166

86

74

-

-

Payments on equipment financings

-

-

-

-

-

-23

-

Payments on supplier and other third-party financings

393

559

465

510

71

192

154

Payments on credit facility

-

1,197

1,934

1,238

625

2,346

-

Net cash provided by financing activities

29,662

23,777

18,588

-

-

-

-

Net increase in Cash

5,878

1,276

-

-

-

-

-

Proceeds from borrowings on line of credit

-

-

-

-

-

365

1,981

Proceeds from issuance of convertible notes and warrants

-

-

-

-

-

175

4,245

Net proceeds from borrowings on credit facility and warrants

-

-

-

-

-

4,897

-

Net cash provided by financing activities

-

-

-

11,936

18,776

20,265

6,086

Net increase in Cash

-

-

-2,462

-4,211

3,456

-

-

Net increase (decrease) in Cash and Cash Equivalents

-

-

-

-

-

5,295

-116

Supplemental Disclosures of Cash Flow Information:
Cash paid during the period for:
Interest

249

605

358

358

405

402

3

Income taxes

-

4

5

2

2

0

0

Gross proceeds from offering

-

-

-

-

-

17,390

-